Hamsa Biopharma, which will take the drug — Christened TGR63 — to trials through its parent company in the US, IGC Pharma, hopes it can eventually be made available in the market.

Researchers in India say they have discovered a promising drug target that may slow or even halt the progression of Alzheimer’s.